Why This IPO Stock, An AnaptysBio Spinoff, Just Surged
First Tracks Biotherapeutics posted "impressive" results for its celiac disease treatment Monday, and the IPO stock surged.
The post Why This IPO Stock, An AnaptysBio Spinoff, Just Surged appeared first on Investor's Business Daily .